Antibiotic

Evolution 2.0 Prize: Unprecedented $10 Million Offered To Replicate Cellular Evolution

Retrieved on: 
Monday, January 13, 2020
Companies, Banks, Finance, Berenberg, Perry Marshall, Antibiotic, Google, Gene

The Evolution 2.0 Prize is designed by Chicago engineer-turned-marketer-turned-business consultant Perry Marshall and his A-list team of partners like top genetic experts from Harvard and Oxford.

Key Points: 
  • The Evolution 2.0 Prize is designed by Chicago engineer-turned-marketer-turned-business consultant Perry Marshall and his A-list team of partners like top genetic experts from Harvard and Oxford.
  • "A germ resisting antibiotics does more programming in 12 minutes than a team of Google engineers can do in 12 days," said Marshall.
  • The full $10 million will only be awarded to a patentable coding system that self-evolves.
  • "If there is a winning entry, it will transform innovation for the next 50-100 years," offered Gary Klopfenstein, former U.S. Director of Berenberg Bank.

Evolution 2.0 Prize: Unprecedented $10 Million Offered To Replicate Cellular Evolution

Retrieved on: 
Monday, January 13, 2020
Articles, Academic disciplines, Artificial intelligence, Computational neuroscience, Cybernetics, Perry Marshall, Antibiotic, Evolution

The Evolution 2.0 Prize is designed by Chicago engineer-turned-marketer-turned-business consultant Perry Marshall and his A-list team of partners.

Key Points: 
  • The Evolution 2.0 Prize is designed by Chicago engineer-turned-marketer-turned-business consultant Perry Marshall and his A-list team of partners.
  • "A germ resisting antibiotics does more programming in 12 minutes than a team of Google engineers can do in 12 days," said Marshall.
  • We are engineers but we're rather poor ones compared to the pseudo engineering that is biological evolution."
  • is literally a million years behind natural intelligence and we want to help researchers figure out the natural code of intelligence inside cells."

EW Nutrition Launches Revolutionary Enzyme in India

Retrieved on: 
Monday, January 13, 2020
Articles, Branches of biology, Health, Extremophiles, Protein structure, Thermostability, Toxicology, Meat industry, Xylanase, Axxess, Nutrition, Antibiotic

HYDERABAD, India, Jan. 13, 2020 /PRNewswire/ -- In December 2019, EW Nutrition has officially launched Axxess XY, a novel, intrinsically thermostable xylanase enzyme that delivers top performance to feed producers and the livestock industry.

Key Points: 
  • HYDERABAD, India, Jan. 13, 2020 /PRNewswire/ -- In December 2019, EW Nutrition has officially launched Axxess XY, a novel, intrinsically thermostable xylanase enzyme that delivers top performance to feed producers and the livestock industry.
  • The revolutionary product was launched at a customer-centric circuit event across five locations in India.
  • With its holistic, science-backed solutions, EW Nutrition has long supported the Indian livestock industry in its effort to improve animal gut health, control toxin risk and reduce antibiotic use.
  • The company is now entering a highly competitive market with a revolutionary solution: Axxess XY, offering the highest level of intrinsic thermostability and acting against both soluble and insoluble arabinoxylans.

ContraFect Partners with Leading Orthopedic Center in Europe to Provide Compassionate Use of Exebacase to Patients with Chronic Staphylococcal Prosthetic Joint Infections

Retrieved on: 
Monday, January 13, 2020
Branches of biology, Microbiology, Medical specialties, Bacteriology, Lysin, Antibiotic, Biofilm, Infectious disease

Based on promising clinical signals in these exebacase-treated patients, temporary authorization for use of exebacase has now been extended to patients with Staphylococcal PJI occurring early in the postoperative period, to potentially avoid significant loss of function.

Key Points: 
  • Based on promising clinical signals in these exebacase-treated patients, temporary authorization for use of exebacase has now been extended to patients with Staphylococcal PJI occurring early in the postoperative period, to potentially avoid significant loss of function.
  • Staphylococcal PJIs pose significant treatment challenges due to biofilm formation which renders conventional antibiotics ineffective and necessitates surgical removal and replacement of the joint.
  • ContraFect is a biotechnology company focused on discovering and developing differentiated biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings.
  • We intend to address life threatening infections using our therapeutic product candidates from our platform of DLAs, which include lysins and amurin peptides.

ContraFect Announces First Patient Dosed in Pivotal Phase 3 DISRUPT Study of Exebacase as a Treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis

Retrieved on: 
Friday, January 10, 2020
Infectious diseases, Medical specialties, Medicine, Bacterial diseases, Healthcare-associated infections, Staphylococcaceae, Bacteremia, Sepsis, Staphylococcus aureus, Placebo-controlled study, Antibiotic, Omadacycline

We believe exebacase and our pipeline of DLA candidates have the potential to be game changers in the fight against drug-resistant pathogens.

Key Points: 
  • We believe exebacase and our pipeline of DLA candidates have the potential to be game changers in the fight against drug-resistant pathogens.
  • The Phase 3 DISRUPT study of exebacase is a randomized, double-blind, placebo-controlled clinical study conducted in the U.S. to assess the efficacy and safety of exebacase in approximately 350 patients with complicated Staph aureus bacteremia, including right-sided endocarditis.
  • Patients entering the Phase 3 study will be randomized 2:1 to either exebacase or placebo, with all patients receiving standard-of-care antibiotics.
  • The primary efficacy endpoint will be clinical response at Day 14 in patients with MRSA bacteremia, including right-sided endocarditis.

Gladskin Launches in USA - Micreos Scaling up to Deliver Award Winning Technology Worldwide

Retrieved on: 
Thursday, January 9, 2020
Medical specialties, Medicine, Micreos, Bacteriophage, Antibiotic, Listeria, Acne, Escherichia coli, Organisms

THE HAGUE, Netherlands, Jan. 9, 2020 /PRNewswire/ -- Dutch biotechnology company Micreos is launching its Gladskin brand in the United States.

Key Points: 
  • THE HAGUE, Netherlands, Jan. 9, 2020 /PRNewswire/ -- Dutch biotechnology company Micreos is launching its Gladskin brand in the United States.
  • With this step, the company reinforces its commitment to make its technology, set to replace antibiotics, available globally.
  • Chosen as Europe's most impactful innovation of 2018, last year alone Gladskin products helped over 100.000 Europeans suffering from eczema, acne and rosacea.
  • Under the Phageguard brand Micreos Food Safety produces several FDA-approved phage products against Listeria, Salmonella and E. coli.

Gladskin Launches in USA - Micreos Scaling up to Deliver Award Winning Technology Worldwide

Retrieved on: 
Thursday, January 9, 2020
Medical specialties, Medicine, Micreos, Bacteriophage, Antibiotic, Listeria, Acne, Escherichia coli, Organisms

THE HAGUE, Netherlands, Jan. 9, 2020 /PRNewswire/ -- Dutch biotechnology company Micreos is launching its Gladskin brand in the United States.

Key Points: 
  • THE HAGUE, Netherlands, Jan. 9, 2020 /PRNewswire/ -- Dutch biotechnology company Micreos is launching its Gladskin brand in the United States.
  • With this step, the company reinforces its commitment to make its technology, set to replace antibiotics, available globally.
  • Chosen as Europe's most impactful innovation of 2018, last year alone Gladskin products helped over 100.000 Europeans suffering from eczema, acne and rosacea.
  • Under the Phageguard brand Micreos Food Safety produces several FDA-approved phage products against Listeria, Salmonella and E. coli.

Microbiology Instrumentation 2019: Molecular Diagnostics, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening & Immunodiagnostics - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 7, 2020
Health, Biotechnology, Antibiotic, Infection, Medical specialties, Medicine, Microbiology

The "Microbiology Instrumentation: Molecular Diagnostics, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, Immunodiagnostics - Infectious Disease Testing Analyzers and Strategic Profiles of Leading Suppliers" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Microbiology Instrumentation: Molecular Diagnostics, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, Immunodiagnostics - Infectious Disease Testing Analyzers and Strategic Profiles of Leading Suppliers" report has been added to ResearchAndMarkets.com's offering.
  • This 86-page report reviews major analyzers used for infectious disease testing, including their operating characteristics, features and selling prices.
  • The report also presents strategic assessments of leading market players and emerging suppliers with innovative technologies and products, including their sales, product portfolios, distribution tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies.

US and EU5 Hand Hygiene Compliance Monitoring Solution Market, Forecast to 2023

Retrieved on: 
Monday, December 30, 2019
Health, Articles, Public health, Evolutionary biology, Pharmaceuticals policy, Veterinary medicine, Antimicrobial resistance, Hand washing, Hygiene, Antimicrobial, Antibiotic

Rising antibiotic and antimicrobial resistance makes it even more critical to identify and implement a solution to control the spread of infections within healthcare settings.

Key Points: 
  • Rising antibiotic and antimicrobial resistance makes it even more critical to identify and implement a solution to control the spread of infections within healthcare settings.
  • The current hand hygiene trend is to use alcohol-based hand solutions, as they are the most effective in most clinical scenarios.
  • In 2018, the hand hygiene solutions and devices market in the United States and the EU5 together generated a revenue of $1.53 billion.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Notice of Q3 Results

Retrieved on: 
Monday, December 16, 2019
Infectious diseases, Medicine, Medical specialties, Antibiotic-resistant bacteria, Healthcare-associated infections, Antibiotic, Clostridioides difficile

Oxford, UK, and Cambridge, MA, US, 16 December 2019 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) a leader in new mechanism antibiotic innovation, will announce its financial results for the third quarter and nine months ended 31 October 2019 on 17 December 2019.

Key Points: 
  • Oxford, UK, and Cambridge, MA, US, 16 December 2019 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) a leader in new mechanism antibiotic innovation, will announce its financial results for the third quarter and nine months ended 31 October 2019 on 17 December 2019.
  • Summit Therapeutics is a leader in antibiotic innovation.
  • Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers.
  • We are currently developing new mechanism antibiotics for infections caused by C. difficile, N. gonorrhoeae and Enterobacteriaceae and are using our proprietary Discuva Platform to expand our pipeline.